game engine
The adjustment in VIP device access rights means that new subscribers will now have the option to access Tencent Video content on up to five devices simultaneously, up from the previous limit of three devices. This change is aimed at providing greater flexibility and convenience for users who consume content across multiple devices, such as smartphones, tablets, smart TVs, and computers.The Cleveland Cavaliers find themselves at home rather than spending a weekend in Las Vegas when they begin the post-NBA Cup portion of their schedule Friday night against the Washington Wizards. The Cavaliers have won 21 of their first 25 games, giving them the best record in the NBA. But two of the four losses came to the Boston Celtics and Atlanta Hawks in group play of the NBA Cup, allowing the Hawks to advance into the event's quarterfinals while the Cavaliers got an unexpected four-day break. Guard Darius Garland believes the time off -- especially following a 122-113 loss at Miami in the team's most recent outing Sunday -- could be a blessing in disguise. "We'll go back to the drawing board," he said of workouts this week. "Get ourselves back together, get our bodies back together and just get ready for Friday." Each team that didn't make the Cup quarterfinals had two games added to its schedule. The Cavaliers caught the easiest of the additions, with a home game against the 3-19 Wizards followed Monday with a trip to Brooklyn to face the 10-14 Nets. According to Power Rankings Guru, the Cavaliers have played the easiest schedule in the NBA. It will get significantly more difficult the rest of the way, rated 17th-hardest among the 30 teams. If previous results this season are an indication, starting with the Wizards should begin a smooth transition. The Cavaliers romped 135-116 at Washington in the first week of the season, and then had an even easier time in a 118-87 home laugher as part of the NBA Cup. The latter win came as part of a four-game winning streak that led into Sunday's loss at Miami. The Wizards went 0-4 in the same NBA Cup group as Cleveland. Those losses were part of an overall 16-game losing streak that ended in a shocking, 122-113 home win over the Denver Nuggets last Saturday. Washington reverted back to previous form when thumped 140-112 by the Memphis Grizzlies at home on Sunday. Like Cleveland, the Wizards have had the last four days off. To add insult to injury, the Wizards' other add-on game will be Sunday at home against the Celtics. Wizards coach Brian Keefe has experience in losing situations. He was on the Oklahoma City coaching staff when the club began the 2008-09 season 3-29. The Thunder made the playoffs the next season, the NBA Finals three years later. "It wasn't like they just rolled out of bed and were winning 50 or 60 games," Keefe recalled. "They had to go through some adversity, and I think we used that adversity as a foundation piece for what we were doing there. "(The Wizards) are working and developing a work rate and effort and habit-building that's setting us up for long-term success." Friday's game matches the NBA leaders in 3-point shooting percentage (Cleveland, 40.4 percent) against the team that has allowed the fourth-highest accuracy rate from beyond the arc (Washington, 37.4 percent). The Cavaliers outscored the Wizards 102-57 on 3-pointers in the first two meetings, with Donovan Mitchell (10-for-19), Sam Merrill (7-for-16) and Garland (6-for-10) combining for 69 of those points. This article first appeared on Field Level Media and was syndicated with permission.
With its planned launch in June or July next year, the Xiaomi YU7 is expected to make a significant impact on the automotive market. As Xiaomi continues to expand its product lineup and diversify its offerings, the Xiaomi YU7 represents a bold step forward for the company, showcasing its ability to innovate and disrupt traditional industry norms.
The attempted assassination of the United Health CEO serves as a stark reminder of the fragility of life and the dangers that can arise in the pursuit of success. It is a sobering moment for the nation as it grapples with the implications of such a senseless act of violence.
AP Sports SummaryBrief at 6:53 p.m. EST
None
South Korean prosecutors have arrested ex-defence Minister Kim Yong-hyun over his alleged role in President Yoon Suk Yeol's declaration of martial law, Yonhap News Agency says. or signup to continue reading Kim, who offered his resignation on Wednesday, was seen as a central figure in Tuesday's brief martial law declaration. A senior military official and filings to impeach Yoon by opposition members said Kim had made the proposal to Yoon. Yoon survived an impeachment vote in parliament on Saturday, prompted by his short-lived attempt to impose martial law, but the leader of his own party said the president would eventually have to step down. The prosecution's special investigative team has questioned Kim, who voluntarily appeared at the Seoul Central District Prosecutors' Office at around 1:30am on Sunday (3:30am AEDT), the report said. The office was not immediately available for comments. Three minority opposition parties filed a complaint with the prosecution against Yoon, Kim and martial law commander Park An-su, accusing them of treason. Kim faces a travel ban as prosecutors investigate, Yonhap said. The national police are also investigating claims of treason against Yoon and top ministers. Yoon shocked the nation on Tuesday night when he gave the military sweeping emergency powers to root out what he called "anti-state forces" and obstructionist political opponents. He rescinded the order six hours later, after parliament defied military and police cordons to vote unanimously against the decree. Yoon's martial law declaration plunged South Korea, Asia's fourth-largest economy and a key US military ally, into its greatest political crisis in decades, threatening to shatter the country's reputation as a democratic success story. Advertisement Sign up for our newsletter to stay up to date. We care about the protection of your data. Read our . AdvertisementThe San Francisco 49ers made it official that Dre Greenlaw will make his long-awaited return from a torn Achilles against the Los Angeles Rams, and the signs are that Nick Bosa will also be available for must-win primetime game. San Francisco confirmed hours before kickoff that linebacker Greenlaw, who suffered his devastating injury running onto the field in the second quarter of Super Bowl 58, had been activated from the PUP list to the 53-man roster. He takes the place of guard Ben Bartch, who has been placed on injured reserve. Star defensive end Bosa, meanwhile, was on Wednesday listed as questionable with the hip/oblique injuries that have seen him miss the last three games. But ESPN's Adam Schefter reported the 2022 Defensive Player of the Year is likely to make his return, though Bosa will test his injuries out pregame before a final decision is made. With the 49ers set to face a Rams offense that was red hot in Los Angeles' thrilling win over the Buffalo Bills last week, the emotional lift from Greenlaw's return and the pass-rushing prowess of Bosa could be huge in allowing San Francisco to slow down Matthew Stafford and Co. On the offensive side of the ball, the 49ers made an additional move, elevating running back Ke'Shawn Vaughn from the practice squad. Vaughn provides extra depth in the backfield with rookie starter Isaac Guerendo battling a foot sprain. Guerendo is expected to play. Israel Abanikanda, claimed off waivers last week after Christian McCaffrey and Jordan Mason suffered season-ending injuries, appears likely to once again be inactive as he acclimates to the offense. This article first appeared on A to Z Sports and was syndicated with permission.
Water Fee to Water Tax: Who is Affected? Residents of 10 Provinces Show Minimal Changes in Water Price Despite Over 7 Years of Pilot Programs with Clear Water Conservation GoalsAP Sports SummaryBrief at 6:53 p.m. EST
Netflix to deliver thrills and drama with Seven Doors, Squid Game: Season 2, The Ultimatum: Marry or Move On: Season 3 and more in December It’s Christmas season and Netflix is delivering all the entertainment. From heart-pounding action and gripping drama to swoon-worthy romance, reality TV thrills, and side-splitting comedy, December is set to be a month to remember. Catch up on titles like the highly anticipated Seven Doors, where a man’s life unravels when he is elected as the new king of his village, only for an ancient prophecy to challenge his reign with blood and fury. A first-time foray into directing by renowned actor, Femi Adebayo, Seven Doors will premiere on Netflix on the 13th of December. Starring leading actors including Muyiwa Ademola, Jide Kosoko, Chioma Akpotha, Adebayo Salami, Ronke Oshodi, Aisha Lawal, Yinka Quadri, Gabriel Afolayan, and Femi Adebayo, the limited series is expected to transport viewers to 18th and 19th century Nigeria. Coming on the heels of Femi Adebayo’s previous project Jagun Jagun, which bagged awards at the AMVCA and AMAA, Seven Doors is expected to be a visionary masterpiece that will have viewers gripped from start to finish. As exciting as Seven Doors is, it’s only one of many titles hitting Netflix in December. On the 1st, there’s a host of titles to choose from. Catch up on Jin: Season 1-2, Firestarter, Taxi Driver, Stealth and Riverdale: Season 7. Start off a binge session with The Ultimatum: Marry or Move On Season 3 on the 4th as six couples test the theory – Is the grass greener on the other side? by moving in with new potential partners for a revealing social experiment. On the 5th, watch Black Doves where a spy posing as a politician’s wife learns her lover has been murdered, and an old assassin friend joins her on a quest for truth — and vengeance. On the 6th, take some time to watch Camp Crasher. Here, in a bid to save her son’s end-of-school camping trip, a single mom steps in as the bus driver while trying to show him she really can be a cool mom. On the 10th, Oscar and Grammy-winner and beloved comedy icon, Jamie Foxx, returns to the stage to set the record straight in a comedy event that celebrates resilience, humour, and the power of community; if he can stay funny, he can stay alive in Jamie Foxx: What Had Happened Was... That same day, check out the shadows of Korea’s rugby world, where seven teams engage in a fierce battle of strength, strategy, and teamwork — all vying to be crowned champion in Rugged Rugby: Conquer or Die The fun continues on the 10th with Polo, a rousing docuseries that goes behind the scenes of professional polo, offering an unprecedented look into the players’ lives on and off the field. On the 12th, watch No Good Deed. In this film, the sale of Paul and Lydia’s picture-perfect LA home forces them to face painful family secrets — and hide them from prying eyes and cutthroat buyers. On the 13th, it’s time for Disaster Holiday. Here, a workaholic dad, trying to win over his kids, heads to the coast of Durban for a big work meeting — under the guise of a family road trip vacation. Follow NFL legend Aaron Rodgers as he bounces back from an Achilles injury in this sports series chronicling the defining moments of his life and career in Aaron Rodgers: Enigma available on the 17th. On the 19th, the sixth season of Virgin River will be available. Here, viewers will experience new beginnings, uncovered secrets and second thoughts: As Mel and Jack prepare for the wedding, they learn more about each other — and their loved ones. A day later, it’s Ferry 2 day! After losing his drug empire, Ferry Bouman has found a measure of peace away from Brabant’s criminal underworld — until his past catches up to him. Lovers of history will have a blast with The Six Triple Eight – Netflix Film also available on the 20th. During World War II, the only Women’s Army Corps unit of colour to serve overseas takes on a seemingly impossible mission in Tyler Perry’s drama inspired by a true story. On the 26th, the show that had the world glued to their screens – Squid Game, makes a comeback. In season 2, a new chapter unfolds as Gi-hun comes back with an agenda, having given up on leaving for the US.The FIFPRO Best 11 of the Year is always a highly anticipated list in the world of football, showcasing the top performers in the sport over the past season. This year's lineup has caused quite a stir among fans and experts, as two of the biggest names in the game, Lionel Messi and Cristiano Ronaldo, find themselves missing out on a spot in the prestigious team.ISRO reschedules Space Docking Experiment by 2 min
Mbappe, known for his blistering pace, exceptional dribbling skills, and clinical finishing, has been a standout player for both club and country. The 22-year-old Frenchman's ability to change the course of a game with his sheer speed and agility has made him a force to be reckoned with on the field. His talent and potential have already seen him compared to some of the all-time greats of the game.
4. Extreme workout routines: Pushing yourself to the limit with intense workout routines may seem like a shortcut to better health and fitness. However, overtraining can lead to injuries, fatigue, and even long-term damage to your body. It is crucial to listen to your body and exercise in moderation to prevent overexertion.
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Chipotle Mexican Grill, Inc. CMG between February 8, 2024 and October 29, 2024, both dates inclusive (the "Class Period") and those who purchased Chipotle call options or sold put options during the Class Period, of the important January 10, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Chipotle securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Chipotle class action, go to https://rosenlegal.com/submit-form/?case_id=30587 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 10, 2025 . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Chipotle's portion sizes were inconsistent and left many customers dissatisfied with the Company's offerings; (2) in order to address the issue and retain customer loyalty, Chipotle would have to ensure more generous portion sizes, which would increase cost of sales; and (3) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Chipotle class action, go to https://rosenlegal.com/submit-form/?case_id=30587 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm . Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
In a stunning turn of events, the long-standing mystery surrounding the murder of a prominent insurance giant CEO has taken a major step towards resolution with the capture of the prime suspect. The case, which has gripped the nation for months, saw a breakthrough as law enforcement officials apprehended the individual believed to be responsible for the heinous crime.COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA ® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. “This marks another step towards achieving our objective to expand SKYTROFA’s label beyond pediatric GHD and expand its reach to address new groups of patients,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Adult GHD is an undertreated condition associated with significant comorbidities and higher annual healthcare costs compared to the 5-10% of patients who receive treatment, indicative of the high unmet need.” The sBLA submission is based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily human growth hormone (hGH) in adults with GHD. The trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy and key secondary efficacy endpoints at Week 38, with TransCon hGH-treated participants showing a statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo. In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH treatment. About Adult Growth Hormone Deficiency Growth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual’s body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression. 1 About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the PDUFA goal date for SKYTROFA, (ii) Ascendis’ objective to expand SKYTROFA’s label and reach to address new groups of patients, (iii) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (iv) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on September 20, 2024 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA ® , are trademarks owned by the Ascendis Pharma group. © December 2024 Ascendis Pharma A/S. 1 . Hoffman AR, Mathison T, Andrews D, Murray K, Kelepouris N, Fleseriu M. Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients' Perspective. J Endocr Soc. 2022;6(7):bvac077. Published 2022 May 12. doi:10.1210/jendso/bvac077
As the market continues to digest the implications of this overnight celebration for Chinese stocks, analysts and investors alike are closely monitoring the next steps for this burgeoning rally. Will the momentum be sustained, or will it fizzle out as quickly as it began? Only time will tell, but one thing is certain – the excitement and optimism surrounding Chinese concept stocks have reached a fever pitch, setting the stage for a potentially transformative period in the world of finance.Fox attorneys seek to dismiss shareholder lawsuit over reporting of vote rigging allegations in 2020